Editor Brian Harrod Provides Comprehensive up-to-date news coverage, with aggregated news from sources all over the world from the Roundup Newswires Network
President Donald Trump's long-promised plan to bring down drug prices, unveiled Friday, would mostly spare the pharmaceutical industry he previously accused of "getting away with murder." Instead he focuses on private competition and more openness to reduce America's prescription pain.
President Donald Trump's long-awaited plan to bring down drug prices, unveiled Friday, will attempt to boost private competition and increase price transparency but drops some of Trump's earlier pledges to strong-arm the pharmaceutical industry at the negotiating table. Trump called his plan the "most sweeping action in history to lower the price of prescription drugs for the American people" in remarks in the White House's Rose Garden.
President Donald Trump's long-promised plan to bring down drug prices, unveiled Friday, would mostly spare the pharmaceutical industry he previously accused of "getting away with murder." Instead he focuses on private competition and more openness to reduce America's prescription pain.
A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period. The hundreds of pending opioid abuse lawsuits likely have just received a jolt from a report from the Senate Committee on Homeland Security and Governmental Affairs linking opioid manufacturers and patient advocacy groups.
Judge Dan Polster poses in his office, Thursday, Jan. 11, 2018, in Cleveland. Polster has invited Ohio's attorney general Mike DeWine to brief him on the impact of the opioid epidemic.
A federal judge who's overseeing lawsuits from around the country against the pharmaceutical industry has invited Ohio's attorney general to brief him on the impact of the opioid epidemic in the state. Judge Dan Polster in Cleveland is overseeing a consolidated case involving dozens of suits filed by communities against drugmakers and drug distributors.
A major trade association for pharmaceutical distributors defended a law that weakened the Drug Enforcement Administration , while ignoring key facts about how the now-stripped power once let the agency suspend distributors that shipped alarming numbers of opioid pills. The pharmaceutical industry - including the Healthcare Distribution Alliance - spent millions lobbying for the Ensuring Patient Access and Effective Drug Enforcement Act, which made it nearly impossible for the DEA to suspend drug distributors if their opioid-based painkiller shipments reached suspicious volumes, The Washington Post and 60 Minutes jointly reported.
Vermont Sen. Bernie Sanders on Monday endorsed Issue 2 on Ohio's November ballot. The proposed law would require the state to spend no more on prescription drugs than the federal Department of Veterans Affairs.
In this June 11, 2009 file photo, Dr. Scott Gottlieb, left, is seen on Capitol Hill in Washington. A White House official says President Donald Trump is choosing Gottlieb, a conservative doctor-turned-pundit with deep ties to Wall Street and the pharmaceutical industry to lead the powerful Food and Drug Administration .
The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased American Depositary Shares of Teva between February 10, 2015 and November 3, 2016 . The case, Galmi v. Teva Pharmaceutical Industries Limited et al , No.
For months, my office has heard from families concerned about their ability to afford a device they desperately need in the event that a loved one suffers a sudden allergic reaction. Parents should not have to worry about whether they can afford an EpiPen for their children.
Mylan NV CEO Heather Bresch faced tough questioning Wednesday from Republicans and Democrats in Congress probing price increases for the EpiPen allergy treatment.
Mylan CEO Heather Bresch takes her seat on Capitol Hill in Washington, Wednesday prior to testifying before the House Oversight Committee hearing on EpiPen price increases. Bresch defended the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers.
The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers. "Price and access exist in a balance, and we believe we have struck that balance," Heather Bresch says in prepared testimony released by the House Oversight and Government Reform Committee ahead of her Wednesday appearance before the panel.
In this file photo, a pharmacist holds a package of EpiPens epinephrine auto-injector, a Mylan product, in Sacramento Mylan CEO Heather Bresch is defending the cost for life-saving EpiPens and is offering no suggestion that there are plans to lower prices. Bresch's prepared testimony was released by the House Oversight and Government Reform Committee ahead of her Sept.
As overdose deaths from prescription painkillers have soared in recent years, members of a loose coalition of drug manufacturers and allied advocacy groups have donated more than $500,000 to state and federal elected officials and political parties in Delaware.
EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. Mylan NL Chief Executive Officer Heather Bresch will appear at a Sept.
Sado-masochism has evidently become the fashion in the pharmaceutical industry. A case in point is Mylan's decision to raise the price of their EpiPen to $600.
Mylan NV's latest attempt to deflect criticism over the price of allergy shot EpiPen failed to get the drugmaker out of the sights of Congress. Last week, Chief Executive Officer Heather Bresch was quick to react to the mounting political scrutiny over EpiPen's price hike with measures to reduce patients' out-of-pocket costs for the shot's $600 brand-name version.
Give Hillary Clinton credit for calling out Mylan NV for price-gouging on its Epi-Pen emergency allergy shot. While a bipartisan group of U.S. Senators initially raised a ruckus over the drug's 400 percent cost increase, it was Clinton's voice that brought pressure to bear on the company to reduce prices.